Peter Vanderslice, PhD

Dr. Vanderslice has spent over 20 years leading teams focused on the development of small molecule compounds that bind and modulate the function of integrins and chemokine receptors. The majority of his professional career has been in the pharmaceutical industry, where he gained familiarity with each stage of the pipeline from discovery to progression into clinical trials. Dr. Vanderslice has led teams working on several pre-clinical programs involving efforts in drug screening, lead compound characterization, and the development of preclinical animal models.

See Publications

Texas Heart Institute Positions


  • Non-invasive diagnostic imaging technologies


  • Undergraduate:

    University of Maryland

  • Postgraduate:

    University of Texas at Austin (PhD)

  • Fellowships:

    University of California San Francisco

Honors, Awards and Memberships


Recent News

New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors

Houston, TX, May 20, 2022 –  Together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas...

Texas Heart Institute Investigators Receive Grant Through NHLBI Catalyze Program

Texas Heart Institute (THI) Molecular Cardiology researchers Peter Vanderslice, PhD, and Ronald J. Biediger, PhD, were recently awarded a grant from...

Alternative Metrics Reveal THI’s Most Popular Scientific Articles from 2021

The impact of a scientific article is often described in terms of how many times the article has been cited...